Key result
SGK1 inhibition shows preclinical efficacy against pressure overload and demonstrates phase 1 clinical safety.
Why the study?
Substantial residual risk persists in HF despite GDMT, requiring novel strategies targeting myocardial metabolic stress, inflammation, fibrosis, and electrical remodeling. Although SGK1 is implicated in pathological remodeling across these domains, clinical translation has been limited by the lack of selective inhibitors.
Does SGK1 inhibition demonstrate preclinical efficacy and phase 1 safety and pharmacodynamic engagement for the treatment of heart failure?
Does SGK1 inhibition demonstrate preclinical efficacy and phase 1 safety and pharmacodynamic engagement for the treatment of heart failure?
Convergent genetic, preclinical, and phase 1 clinical evidence supports the validity, efficacy, safety, and pharmacodynamic engagement of SGK1 inhibition as a novel therapeutic strategy in heart failure.
Answers are grounded in this paper and cite their sources.
Supports advancing SGK1 inhibitors to phase 2 heart failure trials; hypothesis-generating and should not yet change practice.
H eart failure (HF) carries substantial morbidity and mortality despite guidelinedirected medical therapy (GDMT), and residual risk persists after hospitalization for HF with reduced ejection fraction (EF).1,2 Novel strategies addressing myocardial metabolic stress, inflammation, fibrosis, and electrical remodeling are needed.3 Serum/glucocorticoid-regulated kinase 1 (SGK1) is a stress-responsive kinase implicated in pathological structural and electrical remodeling across these domains, but translation has been limited by the lack of selective inhibitors.4,5 Here we present convergent evidence establishing SGK1 target validity through human genetics and cardiac transcriptomics, demonstrating preclinical efficacy in a pressure-overload model, and reporting safety and pharmacodynamic engagement from phase 1 clinical studies.
No takes yet. Share an insight, caveat, or question.
Pradhananga et al. (2026) studied Heart failure. SGK1 inhibition was evaluated on Safety and pharmacodynamic engagement. SGK1 inhibition showed target validity via genetics and transcriptomics, preclinical efficacy in pressure-overload models, and safety and pharmacodynamic engagement in phase 1 clinical studies.
Synapse has enriched 10 related papers. Consider them for comparative context: